1 |
S. C. Currall, E. B. King, N. Lane, J. Madera, and S. Turner, 'What drives public acceptance of nanotechnologies', Nature Nanotech. 1, 153-155 (2006).
DOI
|
2 |
D. Scheufle and B. Lewenstein, 'The public and nanotechnology: How citizens make sense of emerging technologies', J. Nanopart. Res. 7, 659-667 (2005).
DOI
|
3 |
C. Tourney, 'Hearts and minds and nanotechnolgy', Nature Nanotech. 4, 136-137 (2009).
DOI
|
4 |
D. Kahan and D. Rejeski, 'Toward a comprehensive strategy for nanotechnology risk communication', The Project on Emerging Nanotechnologies, April 6 (2009).
|
5 |
M. Siegrist, A. Wiek, A. Helland, and H. Kastenholz, 'Risks and nanotechnology: the public is more concerned than experts and industry', Nature Nanotech. 2, 67 (2007).
DOI
|
6 |
N. Pidgeon, B. H. Harthorn, K. Bryant, and T. R. Hayden, 'Deliberating the risks of nanotechnologies for energy and health applications in the United States and United Kingdom', Nature Nanotech. 4, 95-98 (2007).
|
7 |
The Commission Recommendation on a Code of Conduct for Responsible Nanoscience and Nanotechnologies, (Feb 2008), http://ec.europe.eu/nanotechnology/pdf/nanocode-rec_pe0894c_en.pdf
|
8 |
Y. Song, X. Li, and X. Du, 'Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma', European Respiratory Journal 34, 559-567 (2009).
DOI
|
9 |
NanEX Project FP7 http://www-nanohouse.cea.fr
|
10 |
NanoHOUSE Project FP7 http://www-nanohouse.cea.fr
|
11 |
ECHA Guidance Fact Sheet http://guidance.echa.europa.eu/index_fr.htm
|
12 |
As defined by EU-OSHA (2005), OECD (2003) et ETPIS (2007).
|
13 |
International Risk Governance Council (IRGC) http://www.irgc.org/
|
14 |
FP7 iNTegRisk Project http://www.integrisk.eu-vri.eu/
|
15 |
NanoCode Project FP7 http://www.nanocode.eu
|